Utility of quantitative proteomic technology to diagnoze and classify lymphoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045000

Enrollment

Unknown

Registered

2021-04-03

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

lymphoma group:Nil

Lymphadenitis group:Nil

Tumor metastatic lymph node group:Nil

non-neophlastic lymph node group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Aged older than 14 years. 2.Admitted to our hospital and suspected diagnosed with lymphoma from May 2015 to 2019. 3.Lymph node tissue stored at our biobank.

Exclusion criteria

Exclusion criteria: 1.Who had HIV disease; 2.Clinical information related to diagnosis and treatment response was unavailable; 3.Who complicated by another cancer; 4.Pregnancy with lymphoma; 5.Who had some medical conditions inappropriate for the study and affected to follow up,the condiction was determined by the researchers.

Design outcomes

Primary

Measure	Time frame
Differently expressed protein;	—

Countries

China

Contacts

Public ContactJin Jie

The First Hospital affiliated to Zhejiang University School of Medicine

1513084@zju.edu.cn+86 571 87236898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026